Loading clinical trials...

RECRUITINGPHASE3

Androgenic Alopecia TH07 Clinical Trial

Phase III, Parallel Design, Triple-Blind, Randomized, Multicenter Clinical Trial to Evaluate Safety & Efficacy of TH07 Topical Treatment in Male Patients With Androgenic Alopecia.

NCT07435012•Triple Hair Inc

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.

Detailed Description

The MATT study is a Phase III clinical trial designed to evaluate the safety and effectiveness of a new topical hair growth treatment called TH07. TH07 is a combined topical spray solution containing three active ingredients commonly used to treat hair loss: Minoxidil (5%) Finasteride (0.1%) and Latanoprost (0.03%). The study plans to enroll 420 men aged 18 to 49 years old across up to 10 clinical sites. Participants will be randomly assigned to one of four groups to receive either TH07 (once or twice daily), a standard Minoxidil solution, or a placebo. The treatment will be applied daily (once or twice) for 24 weeks.

Eligibility

Age

18 - 49 years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Males, 18 to 49 years of age on the date of enrollment.
•Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale.
•Body Mass Index (BMI) in the range of 19 to 35 kg/m2.
•Not administered any systemic or topical treatment for AGA during the last 90 days.
•Willing to comply with the following restrictions for the duration of trial participation:
•1. Any systemic or topical treatment of any system of medicine (other than trial treatment) for AGA.
•2. Hair dyes, hair texturizers, relaxers etc.
•3. Any new vitamins or nutritional supplements that are currently not being administered.
•4. Tattooing in the trial target area.
•5. Blood donations.
+8 more criteria

Exclusion Criteria

•History of scalp treatment including though not limited to any of the following:
•1. Hair transplant or extension surgery.
•2. Hair weaving.
•3. Laser or light therapy on the scalp in the last 6 months.
•4. Micro-needling or intradermal therapy (mesotherapy) on the scalp including PRP in the last 6 months.
•5-Any other surgical treatment for hair loss
•Any of the following hair styles:
•1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.
•Known or presumed hypersensitivity to any trial treatment medication; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of investigator may affect the outcome of trial.
•Any other significant abnormalities indicating of severe, acute or chronic medical condition(s) that may lead to hair loss or otherwise interfere with the interpretation of trial results.
+4 more criteria

Locations (1)

YVR Aesthetic Training and Study Centre.

Vancouver, British Columbia, Canada

Key Dates

Start Date

April 1, 2026

Primary Completion Date

December 1, 2027

Completion Date

April 1, 2028

Last Updated

March 16, 2026

Enrollment

420

ESTIMATED participants

Conditions

Androgenic Alopecia

Interventions

TH07

DRUG

TH07

DRUG

Minoxidil 5% Topical Solution

DRUG

Placebo

OTHER

Contacts

Edouard AL-Chami

CONTACT

647-453-3253 ealchami@triplehair.ca

Lori Hebert

CONTACT

lhebert@triplehair.ca

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

NCT07107841

Androgenic AlopeciaAlopecia+1 more

View study

NOT_YET_RECRUITINGEARLY_PHASE1

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

NCT03474718

Androgenic Alopecia

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 16, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Androgenic Alopecia TH07 Clinical Trial

Inclusion Criteria

Exclusion Criteria

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

Fractional Laser Versus Radiofrequency in Androgenetic Alopecia

Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia